Hoe verhoudt 290A's PB Ratio zich tot zijn concurrenten?

290A is duur op basis van de Price-To-Book -ratio ( 8.1 x) vergeleken met het gemiddelde van de peer ( 4.9 x).

Hoe verhoudt 290A's PB Ratio zich tot andere bedrijven in de DE Biotechs industrie?

290A is duur op basis van de Price-To-Book -ratio ( 8.1 x) vergeleken met het German Biotechs -industriegemiddelde ( 2 x).

Wat is 290A's PB Ratio vergeleken met zijn Fair PB Ratio? Dit is de verwachte PB Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

Onvoldoende gegevens om de Price-To-Book Fair Ratio van { 290A te berekenen voor waarderinganalyse.

Wat is de reële prijs van 290A als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

Onvoldoende gegevens om de reële waarde van 290A te berekenen voor waarderingsanalyse.

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

De koersdoelstelling is lager dan de huidige aandelenkoers.

Chinook Therapeutics (DB:290A) - Aandelenkoers, Nieuws & Analyse

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

290A Overzicht aandelen

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. Meer informatie

290A fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 63.8% per jaar groeien

Risicoanalyse

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Aandeelhouders zijn het afgelopen jaar verwaterd

Chinook Therapeutics, Inc. Concurrenten

Biotest

XTRA:BIO3

€1.4b

Formycon

XTRA:FYB

€844.9m

MorphoSys

XTRA:MOR

€2.5b

Heidelberg Pharma

XTRA:HPHA

€106.7m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Chinook Therapeutics
Historische aandelenkoersen
Huidige aandelenkoers	US$36.40
52 Week Hoogtepunt	US$37.40
52 Week Laag	US$16.80
Bèta	0.67
11 maand verandering	3.41%
3 maanden verandering	75.00%
1 Jaar Verandering	89.58%
33 jaar verandering	n/a
5 jaar verandering	n/a
Verandering sinds IPO	197.82%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	290A	DE Biotechs	DE Markt
7D	0.6%	0.8%	0.8%
1Y	89.6%	-18.3%	8.6%

Rendement versus industrie: 290A overtrof de German Biotechs industrie, die het afgelopen jaar een rendement -18.3 % opleverde.

Rendement versus markt: 290A overtrof de German markt, die het afgelopen jaar een rendement opleverde van 8.6 %.

Prijsvolatiliteit

Is 290A's price volatile compared to industry and market?
290A volatility
290A Average Weekly Movement	20.0%
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: De aandelenkoers van 290A is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van 290A is het afgelopen jaar gestegen van 11% naar 20%.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
n/a	214	Eric Dobmeier	www.chinooktx.com

Chinook Therapeutics, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Chinook Therapeutics zich tot de beurswaarde?
290A fundamentele statistieken
Marktkapitalisatie	€2.65b
Inkomsten(TTM)	-€224.40m
Inkomsten(TTM)	€5.34m

495.8x

P/S-verhouding

-11.8x

Koers/Winstverhouding

Is 290A overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
290A resultatenrekening (TTM)
Inkomsten	US$5.85m
Kosten van inkomsten	US$193.72m
Brutowinst	-US$187.87m
Overige uitgaven	US$57.79m
Inkomsten	-US$245.65m

Laatst gerapporteerde inkomsten

Jun 30, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-3.42
Brutomarge	-3,211.95%
Nettowinstmarge	-4,199.93%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde 290A op de lange termijn?

Bekijk historische prestaties en vergelijking

This company listing is no longer active

290A Overzicht aandelen

Beloningen

Risicoanalyse

Chinook Therapeutics, Inc. Concurrenten

XTRA:BIO3

€1.4b

XTRA:FYB

€844.9m

XTRA:MOR

€2.5b

XTRA:HPHA

€106.7m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Novartis AG (SWX:NOVN) completed the acquisition of Chinook Therapeutics, Inc. (NasdaqGS:KDNY) from a group of shareholders.

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from NASDAQ Biotechnology Index

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from S&P TMI Index

Second quarter 2023 earnings released: US$0.94 loss per share (vs US$0.61 loss in 2Q 2022)

Chinook Therapeutics, Inc. Announces the First Patient Enrolled in its Phase 3 Second Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy

Chinook Therapeutics, Inc. Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failure Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress

Recent updates

Novartis AG (SWX:NOVN) completed the acquisition of Chinook Therapeutics, Inc. (NasdaqGS:KDNY) from a group of shareholders.

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from NASDAQ Biotechnology Index

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from S&P TMI Index

Second quarter 2023 earnings released: US$0.94 loss per share (vs US$0.61 loss in 2Q 2022)

Chinook Therapeutics, Inc. Announces the First Patient Enrolled in its Phase 3 Second Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy

Chinook Therapeutics, Inc. Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failure Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress

Chinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) Congress

First quarter 2023 earnings released: US$0.85 loss per share (vs US$0.54 loss in 1Q 2022)

Independent Lead Director recently sold €5.6m worth of stock

Full year 2022 earnings released: US$2.87 loss per share (vs US$2.26 loss in FY 2021)

Chinook Therapeutics, Inc. Appoints Andrew Oxtoby as Chief Commercial Officer

President recently sold €175k worth of stock

Third quarter 2022 earnings released: US$0.83 loss per share (vs US$0.69 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.83 loss per share (vs US$0.69 loss in 3Q 2021)

Chinook Therapeutics, Inc. Presents Updated Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort, Preclinical Atrasentan Research and Ongoing Clinical Trials at the American Society of Nephrology (ASN) Kidney Week 2022

Independent Director recently bought €212k worth of stock

Second quarter 2022 earnings released: US$0.61 loss per share (vs US$0.97 loss in 2Q 2021)

High number of new directors

President recently bought €61k worth of stock

Chinook Therapeutics, Inc. Presents Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort and Evotec Collaboration at 59th European Renal Association Congress 2022

Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and from Atrasentan Preclinical Mechanism of Action Studies at the 59th European Renal Association (ERA) Congress 2022

First quarter 2022 earnings released: US$0.54 loss per share (vs US$0.88 loss in 1Q 2021)

High number of new directors

Chinook Therapeutics, Inc., Annual General Meeting, May 26, 2022

Chinook Therapeutics Announces Initiation of Phase 1 Healthy Volunteer Trial of CHK-336, a First-in-Class LDHA Inhibitor to Treat Hyperoxalurias

High number of new directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Chinook Therapeutics, Inc. Announces Resignation of Alan Glicklich as Chief Medical Officer, Effective February 11, 2022

High number of new directors

President recently bought €101k worth of stock

Sairopa B.V., entered into an agreement to acquire non-renal assets of Chinook Therapeutics, Inc.

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from Russell Microcap Growth Index

Chinook Therapeutics Presents BION-1301 Interim Phase 1/2 Data in Patients with IgA Nephropathy (IgAN) at the 58th ERA-EDTA Virtual Congress

Chinook Therapeutics, Inc. announced delayed annual 10-K filing

Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 Align Study of Atrasentan for Patients with Iga Nephropathy

Chinook Therapeutics, Inc. and Evotec SE Announce Strategic Collaboration to Discover and Develop Novel Precision Medicines for Chronic Kidney Diseases

Chinook Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Chk-336 for Treatment of Primary Hyperoxaluria

Chinook Therapeutics Announces License Agreement with Morehouse School of Medicine for Development of Therapies in Kidney Diseases Disproportionately Affecting African Americans and Underserved Communities

President recently bought €53k worth of stock

Chinook Therapeutics Announces Appointment of Eric Bjerkholt as Chief Financial Officer

Chinook Therapeutics, Inc. Provides Business Update

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Chinook Therapeutics, Inc. Samenvatting

495.8x

-11.8x

Inkomsten en omzet